ACY1
ACY1 (aminoacylase 1) is a cytosolic, zinc-binding enzyme that hydrolyses N-acetylated and N-formylated amino acids into free amino acids and a carboxylate. It belongs to the peptidase M20A family and is thought to contribute to the catabolism and salvage of acylated amino acids. Browse Assay Genie's current range of ACY1 research reagents below, or read on for the biology behind the target.
ACY1 is an aminoacylase that catalyses the hydrolysis of acylated L-amino acids to L-amino acids and an acyl group, with activity towards N-acetylated and N-formylated amino acids. It has been postulated to function in the catabolism and salvage of acylated amino acids. UniProt notes that it may act sequentially with APEH in the degradation of N-acylated peptides: APEH first cleaves N-acylamino acids from N-acylated peptides, and ACY1 then hydrolyses the N-acylamino acid into a free amino acid and a carboxylate.
The ACY1 gene encodes a cytosolic, homodimeric, zinc-binding enzyme assigned to the M20 metallopeptidase group and the peptidase M20A family. Human aminoacylase-1 is highly homologous to the porcine counterpart, and it was described as the first member of a new family of zinc-binding enzymes. Alternative splicing of the gene gives multiple transcript variants. Read-through transcription also occurs between ACY1 and the upstream ABHD14A gene, and a related pseudogene has been identified on chromosome 18. Mouse and rat orthologs are designated Acy1 and Acy1a respectively.
Mutations in the ACY1 gene cause aminoacylase-1 deficiency, a metabolic disorder characterised by central nervous system defects and increased urinary excretion of N-acetylated amino acids. The gene lies in a chromosomal region reduced to homozygosity in small-cell lung cancer (SCLC), and its expression has been reported to be reduced or undetectable in SCLC cell lines and tumours. These links make ACY1 protein a point of interest in both inborn errors of metabolism and lung cancer research.
ACY1 hydrolyses N-acetylated and N-formylated amino acids and is thought to support the catabolism and salvage of acylated amino acids.
Mutations in ACY1 cause aminoacylase-1 deficiency, marked by central nervous system defects and raised urinary excretion of N-acetylated amino acids.
ACY1 maps to a region reduced to homozygosity in SCLC, and its expression is reported to be reduced or undetectable in SCLC lines and tumours.
ACY1 may act after APEH, which releases N-acylamino acids from N-acylated peptides, to yield free amino acids and a carboxylate.
ACY1 is a cytosolic zinc-binding aminoacylase that hydrolyses N-acetylated and N-formylated amino acids into free amino acids and a carboxylate. It may work sequentially with APEH, which first releases N-acylamino acids from N-acylated peptides, in the degradation of those peptides.
ACY1 is the HGNC symbol for aminoacylase 1, and UniProt names the protein aminoacylase-1. No alternative symbols are listed. Alternative splicing produces multiple transcript variants, and read-through transcription links the gene with upstream ABHD14A.
Human aminoacylase-1 is highly homologous to the porcine enzyme, and mouse (Acy1) and rat (Acy1a) orthologs exist. Mutations cause aminoacylase-1 deficiency, and expression is reported to be reduced in small-cell lung cancer. Check the datasheet of any product for its validated reactivity.
Other acyl-handling enzymes and metabolic targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q03154; product specifications from Assay Genie datasheets.